Penbrook Management LLC Sells 7,270 Shares of BioLife Solutions, Inc. $BLFS

Penbrook Management LLC cut its stake in shares of BioLife Solutions, Inc. (NASDAQ:BLFS) by 23.9% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 23,155 shares of the medical equipment provider’s stock after selling 7,270 shares during the period. Penbrook Management LLC’s holdings in BioLife Solutions were worth $499,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. State of Wyoming lifted its stake in BioLife Solutions by 353.1% during the 1st quarter. State of Wyoming now owns 1,912 shares of the medical equipment provider’s stock valued at $44,000 after acquiring an additional 1,490 shares in the last quarter. US Bancorp DE increased its position in shares of BioLife Solutions by 243.7% during the 1st quarter. US Bancorp DE now owns 2,155 shares of the medical equipment provider’s stock valued at $49,000 after purchasing an additional 1,528 shares during the last quarter. GAMMA Investing LLC increased its position in shares of BioLife Solutions by 18.6% during the 1st quarter. GAMMA Investing LLC now owns 4,223 shares of the medical equipment provider’s stock valued at $96,000 after purchasing an additional 663 shares during the last quarter. Strs Ohio purchased a new stake in shares of BioLife Solutions during the 1st quarter valued at $153,000. Finally, Avantax Advisory Services Inc. increased its position in shares of BioLife Solutions by 16.0% during the 1st quarter. Avantax Advisory Services Inc. now owns 9,077 shares of the medical equipment provider’s stock valued at $207,000 after purchasing an additional 1,250 shares during the last quarter. 93.24% of the stock is currently owned by institutional investors.

BioLife Solutions Stock Performance

Shares of BLFS opened at $27.42 on Tuesday. The business has a 50-day moving average of $25.21 and a 200 day moving average of $23.33. BioLife Solutions, Inc. has a fifty-two week low of $19.10 and a fifty-two week high of $29.55. The firm has a market cap of $1.31 billion, a P/E ratio of -228.48 and a beta of 1.95.

BioLife Solutions (NASDAQ:BLFS) last announced its quarterly earnings data on Thursday, August 7th. The medical equipment provider reported ($0.33) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.31). BioLife Solutions had a positive return on equity of 0.16% and a negative net margin of 5.39%.The firm had revenue of $25.42 million during the quarter, compared to analysts’ expectations of $23.71 million. BioLife Solutions has set its FY 2025 guidance at EPS. As a group, research analysts predict that BioLife Solutions, Inc. will post -0.3 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on BLFS shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioLife Solutions in a research report on Wednesday, October 8th. HC Wainwright reaffirmed a “buy” rating and set a $32.00 target price (up from $30.00) on shares of BioLife Solutions in a research report on Friday, August 8th. Zacks Research lowered BioLife Solutions from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 7th. Finally, Stephens started coverage on BioLife Solutions in a research report on Tuesday, July 22nd. They set an “overweight” rating and a $30.00 target price for the company. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $31.29.

Insider Buying and Selling at BioLife Solutions

In other BioLife Solutions news, CMO Todd Berard sold 10,000 shares of BioLife Solutions stock in a transaction dated Monday, August 25th. The stock was sold at an average price of $25.53, for a total transaction of $255,300.00. Following the completion of the transaction, the chief marketing officer owned 124,618 shares of the company’s stock, valued at $3,181,497.54. The trade was a 7.43% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Casdin Partners Master Fund, L sold 500,000 shares of BioLife Solutions stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $24.40, for a total value of $12,200,000.00. Following the transaction, the insider directly owned 6,707,165 shares of the company’s stock, valued at $163,654,826. The trade was a 6.94% decrease in their position. The disclosure for this sale can be found here. Insiders sold 1,016,883 shares of company stock valued at $23,929,762 in the last quarter. 2.20% of the stock is currently owned by corporate insiders.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.